Emphasising the European Union's commitment to cancer research: A helicopter view of the Seventh Framework Programme for Research and Technological Development

Oncologist

Volumn 17, Issue 10, 2012, Pages

  Van De Loo, Jan Willem ^a   Trzaska, Dominika ^a   Berkouk, Karim ^a   Vidal, Maria ^a   Draghia Akli, Ruxandra ^a  

^a EUROPEAN COMMISSION   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TENASCIN;

ARTICLE; BUDGET; CANCER CENTER; CANCER CONTROL; CANCER GROWTH; CANCER RESEARCH; CANCER RISK; DRUG APPROVAL; DRUG COST; DRUG SAFETY; DRUG SCREENING; EUROPEAN UNION; FUNDING; HUMAN; METASTASIS; MORBIDITY; MORTALITY; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; SIGNAL TRANSDUCTION; SURVIVAL;

ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTOR, ERBB-2;

EID: 84868117167     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0327     Document Type: Article

References (55)

1. Malvezzi M, Bertuccio P, Levi F et al. European cancer mortality predictions for the year 2012. Ann Oncol 2012;23:1044-1052.
2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-781.
3. World Health Organization. The global burden of disease: 2004 update. Geneva, Switzerland:WHOPress, 2008:1-146.
4. Decision No 1513/2002/EC of the European Parliament and of the Council of 27 June 2002 concerning the Sixth Framework Programme of the European Community for Research, technological development and demonstration activities, contributing to the creation of the European Research Area and to innovation (2002-2006). Available at http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri_ CELEX:32002D1513:EN:HTML, accessed August 7, 2012.
5. Decision No 1982/2006/EC of the European Parliament and of the Council of 18 December 2006 concerning the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007-2013). Available at http://eur-lex.europa.eu/JOHtml.do?uri_OJ:L:2006: 412:SOM:EN:HTML, accessed August 7, 2012.
6. Jungbluth S, Kelm O, van de Loo JW et al. Europe combating cancer: The European Union's commitment to cancer research in the 6th Framework Programme. Mol Oncol 2007;1:14-18.
7. Community Research and Development Information Service CORDIS. FP7 specific programme cooperation. Available at http://cordis.europa.eu/fp7/cooperation/home_en.html, accessed August 7, 2012.
8. Community Research and Development Information Service. FP7 Health Research homepage. Available at http://cordis.europa.eu/fp7/health/home_en.html, accessed August 7, 2012.
9. International Cancer Research Partnership. CommonScientific Outline classification system. Available at https://www. icrpartnership.org/CSO.cfm, accessed August 7, 2012.
10. Gatta G, van der Zwan JM, Casali PG et al. Rare cancers are not so rare: The rare cancer burden in Europe. Eur J Cancer 2011;47:2493-2511.
11. Verdecchia A, Francisci S, Brenner H et al. Recent cancer survival in Europe:A2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007;8:784-796.
12. Verdecchia A, Santaquilani M, Sant M. Survival for cancer patients in Europe. Ann Ist Super Sanita. 2009;45;315-324.
13. Brenner H, Francisci S, de Angelis R et al. Longterm survival expectations of cancer patients in Europe in 2000-2002. Eur J Cancer 2009;45:1028-1041.
14. CancerPathways. Project homepage: Available at http://www.cancerpathways.eu, accessed August 7, 2012.
15. NEXT-RNAi. Software homepage. Available at http://www.nextrnai.org, accessed August 7, 2012.
16. Web cellHTS2. Software homepage. Available at http://web-cellhts2.dkfz.de/cellHTS-java/cellHTS2/, accessed August 7, 2012.
17. CancerPathways. GenomeRNAi and FLIGHT databases homepage. Available at http://www.cancerpathways. eu/SearchGeneRNAi/, accessed August 7, 2012.
18. Horn T, Sandmann T, Fischer B et al. Mapping of signalling networks through synthetic genetic interaction analysis by RNAi. Nat Methods 2011;8:341-346.
19. Antibody Derivatives As Molecular Agents for Neoplastic Targeting. ADAMANT project homepage. Available at http://www.adamant-fp7.eu/index.php, accessed August 7, 2012.
20. Silini A, Ghilardi C, Figini S et al. Regulator of Gprotein signaling 5 (RGS5) protein: A novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment. Cell Mol Life Sci 2012;69:1167-1178.
21. Pedretti M, Verpelli C, Mårlind J et al. Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma. Br J Cancer 2010;103:827-836.
22. Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10:767-777.
23. Inflammation and Cancer Research in Europe. INFLA-CARE project homepage. Available at: http://inflacare.imbb.forth.gr/, accessed August 7, 2012.
24. Delahaye NF, Rusakiewicz S, Martins I et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 2011;17:700-707.
25. Welz PS, Wullaert A, Vlantis K et al. FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation. Nature 2011;477:330-334.
26. Golomb L, Bublik DR, Wilder S et al. Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis. Mol Cell 2012;45:222-232.
27. Perkins ND. The diverse and complex roles of NF-αB subunits in cancer. Nat Rev Cancer 2012;12:121-132.
28. European Commission. European Clinical Trials in Rare Sarcomas within an integrated translational trial networkEUROSARC. Availableathttp://www.eurosarc. eu, accessed August 7, 2012.
29. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-715.
30. Walker I, Newell H. Do molecularly targeted agents in oncology have reduced attrition rates? Nat Rev Drug Discov 2009;8:15-16.
31. Arrowsmith J. Trial watch: Phase III and submission failures: 2007-2010. Nat Rev Drug Discov 2011;10:87.
32. Berggren R, Møller M, Mosset R et al. Outlook for the next 5 years in drug innovation. Nat Rev Drug Discov 2012;11:435-436.
33. Innovative Medicines Initiative. Available at http://www.imi.europa.eu/, accessed August 7, 2012.
34. OncoTrack. Project homepage. Available at http://www.oncotrack.org/, accessed August 7, 2012.
35. Elsner M. OncoTrack tests drugs in virtual people. Nat Biotechnol 2011;29:378.
36. Quantitative Imaging in Cancer: Connecting Cellular Processes with Therapy. QUIC-CONCEPT project homepage. Available at http://www.quic-concept.eu/, accessed August 7, 2012.
37. Innovative Medicines Initiative. MARCAR project homepage: Available at http://www.imi-marcar.eu/, accessed August 7, 2012.
38. Lempiäinen H, Müller A, Brasa S et al. Phenobarbital mediates an epigenetic switch at the constitutive androstane receptor (CAR) target gene Cyp2b10 in the liver of B6C3F1 mice. PLoS One 2011;6:e18216.
39. Kanavos P, Sullivan R, LewisonGet al. The role of funding and policies on innovation in cancer drug development. Ecancermedicalscience 2010;4:1-139.
40. FP5: Decision No 182/1999/EC of the European Parliament and of the Council of 22 December 1998 concerning the fifth Framework Programme of the European Community for research, technological development and demonstration activities (1998 to 2002). Available at http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri_CELEX:31999D0182:EN: NOT, accessed August 7, 2012.
41. European Forum for Cancer Research Management (ECRM). Available at http://cordis.europa.eu/search/index.cfm?fuseaction_proj.printdocument&PJ_ RCN_5674531, accessed August 7, 2012.
42. Eurocan Plus report: Feasibility study for coordination of national cancer research activities. Ecancermedicalscience. 2008;2:84.
43. Europe against Cancer: Optimisation of the Use of Registries for Scientific Excellence in Research EUROCOURSE. Project homepage. Available at http://www.eurocourse.org/, accessed August 7, 2012.
44. EurocanPlatform project homepage. Available at http://eurocanplatform.eu/, accessed August 7, 2012.
45. European Research Area Network on Translational Cancer Research. TRANSCAN project homepage. Available at http://www.transcanfp7.eu/transcan/index. php, accessed August 7, 2012.
46. European Partnership for Action Against Cancer. EPAAC homepage. Available at http://www.epaac.eu/home, accessed August 7, 2012.
47. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
48. International Cancer Genome Consortium. ICGC homepage. Available at http://www.icgc.org, accessedAugust 7, 2012.
49. CAGEKID project homepage. Available at http://www.cng.fr/cagekid/, accessed August 7, 2012.
50. BASIS project homepage. Available at http://www.basisproject.eu/, accessed August 7, 2012.
51. European Research Council. Available at http://erc.europa.eu/, accessed August 7, 2012.
52. European Commission. FP7 Marie Curie Actions: Research Fellowship Programme. Available at http://ec.europa. eu/research/mariecurieactions/, accessed August 7, 2012.
53. European Commission, Research, and Innovation. Participant portal. Available at http://ec.europa.eu/research/participants/portal/page/cooperation#health, accessed August 7, 2012.
54. European Commission. Horizon 2020. The EU Framework Programme for Research and Innovation. Available at http://ec.europa.eu/research/horizon2020/index_en.cfm/, accessed August 7, 2012.
55. Draghia-Akli R. A new Horizon. Public Service Review: European Union 2012;23:162-163.